Brief: VTI Announces Positive Interim 1-Year Data From Protect Clinical Trial At American Academy Of Optometry Annual Meeting
12/10/2023 15:25
Oct 12 (Reuters) - Visioneering Technologies Inc
VTI.AX :
* VTI ANNOUNCES POSITIVE INTERIM 1-YEAR DATA FROM THE
PROTECT
CLINICAL TRIAL AT AMERICAN ACADEMY OF OPTOMETRY ANNUAL MEETING
* VISIONEERING TECHNOLOGIES INC - NATURALVUE(®) MULTIFOCAL 1
DAY
CONTACT LENSES CONFIRMED SAFE & EFFECTIVE FOR MYOPIA MANAGEMENT
* VISIONEERING TECHNOLOGIES INC - PRELIMINARY 1-YEAR
FINDINGS
AFFIRMED NVMF'S EFFECTIVENESS IN SLOWING MYOPIA PROGRESSION
* VISIONEERING TECHNOLOGIES INC - FURTHER REVIEW AND
ANALYSIS TO
BE COMPLETED FOR PRELIMINARY DATA; ADDITIONAL INSIGHTS TO BE
SHARED IN JANUARY 2024
Source text for Eikon: ID:nBw8yVHcha
Further company coverage: VTI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Visioneering Technologies
See all newsBrief: Visioneering Technologies Inc Appoints Jeff Pruett As CFO
Brief: Visioneering Technologies To Be Removed From ASX
Brief: Visioneering Technologies Requests Delisting From ASX
Brief: Visioneering Technologies Seeks Trading Halt Pending Announcement On Application To Be Made For Co To Be Removed From Official List
Brief: Visioneering Technologies Posts Qtrly Net Revenue $2.3 Mln